Vendor Intelligence Report: Xian Yihang Technology
Published 12 Nov 2026. 36-page investigative report on who is behind Xian Yihang Technology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Xian Yihang Technology is not a ghost vendor: this report ties TopXPeptide, the Yihang B2B site, LookChem and the active eCHEMI shop to a documented Xi’an operating company. But the identity record is narrower than the sales story: license and WHOIS evidence support a recent trading/export entity, while the shareholder layer remains unresolved and the registered address reads like a cluster-registration suite, not a verified factory.
Across 81 Finnrick lab tests, the overall pass rate is 70% (57 pass / 24 fail). The catalog is uneven: GHK-Cu and Tirzepatide are the strongest practical rows, while TB-500 and Tesamorelin are the clearest switch-away signals. The full report shows the complete product breakdown and how stricter scoring changes the public purity-focused view.
The non-lab findings affect trust in claims and channels. A public management profile carries an older founding story and a 10,000-ton 5-HMF project; formation records and Chinese-source project coverage point elsewhere. OptimalLab, PepSource and PeptideAtlas artifacts show YH/TopXPeptide material surfacing through white-label or downstream sellers, while lookalike YH domains and removed, unavailable or de-branded review/social surfaces complicate seller authentication.
The buyer takeaway is directional, not a blanket rejection. Stronger products still require a recent, lot-numbered COA with a lab verification route; weaker rows should be avoided where better-testing alternatives exist. The report also documents what public sources did, and did not, establish about technical oversight and batch-release authority.
Inside the full report:
- Appendix A — Finnrick Laboratory Data with per-product pass/fail, rating trajectories and methodology-divergence charts for all 8 products
- Business license, LookChem verification, WHOIS and eCHEMI records tying TopXPeptide/yihangbec to 西安翼航生物有限公司
- Claim-vs-record analysis of the founding-year, warehouse/global-reach and 5-HMF project statements
- White-label and downstream batch trail through OptimalLab, PepSource and PeptideAtlas
- YH brand-confusion map covering TopXPeptide, HNYH/yh-peptide.com and yhpeptide.com
- Storefront and reputation artifacts: Trustpilot removal, Facebook unavailability, TikTok de-branding and ThinkPHP debug pages
Risk assessment
- Weak product-specific testing record — high: TB-500 (40.93%), Tesamorelin (51.05%), Ipamorelin (62.38%) and Semaglutide (62.28%) materially trail this vendor’s stronger GHK-Cu/Tirzepatide/Retatrutide rows.
- Marketing-claims integrity risk — high: Sam Zhang/Yihang materials conflict with the current 2024 license and misattribute Tangneng’s 10,000-ton 5-HMF project to Yihang.
- Ownership and entity-transparency concern — medium: Legal entity and legal representative are documented, but the shareholder/UBO layer was not obtained; the registered address is a cluster suite and Chemical/Biological naming remains unresolved.
- Brand-confusion and channel-authentication risk — medium: YH Peptide is used by multiple unproven operations (TopXPeptide, HNYH/yh-peptide.com, yhpeptide.com), and no official channel/reseller list or anti-counterfeit portal was found.
- White-label and downstream-reseller dependency risk — medium: OptimalLab names topxpeptide.com as manufacturer for a YH Peptide MOTS-C COA, PepSource/Biocompounds carry YH-prefixed batches, and secondary reporting places TopXPeptide in a downstream non-payment dispute.
- Storefront reliability and buyer-protection gaps — medium: TopXPeptide category pages returned debug errors; Peptide Referee found no shipping/refund/terms/payment pages and generic COA material without visible lot numbers.
- Product-category legal/customs exposure — medium: The catalog includes anabolic steroids, SARMs and PDE5 inhibitors in addition to peptides, adding destination-country customs or prescription/controlled-substance exposure for those products.
- Reputation-surface contraction concern — medium: Trustpilot profile removed, Facebook pages unavailable and TikTok sales persona de-branded, reducing independent review and channel-verification surfaces.